Loading...
Market
How will Organon's stock price change by December 31, 2024, post-acquisition?
3
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Stock market data from financial news platforms like Bloomberg or Yahoo Finance
Story
Organon to Acquire Roivant's Dermavant for Up to $1.2 Billion, Including VTAMA Cream
Sep 18, 2024, 01:15 PM
Organon has announced its acquisition of Dermavant, a subsidiary of Roivant Sciences, in a deal valued at up to $1.2 billion. The acquisition includes Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) Cream 1%. Organon will pay $175 million upfront, with additional payments contingent on regulatory approval and sales milestones. Specifically, $75 million will be paid upon approval of VTAMA for atopic dermatitis, and up to $950 million will be paid based on sales milestones. Roivant's stock rose 2.2% pre-market following the announcement. The deal has received mixed reactions from analysts, with some expressing concerns about its impact on Organon, while others view it as positive for Roivant.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by up to 10% • 25%
Decrease by up to 10% • 25%
Decrease by more than 10% • 25%
Less than $25 • 25%
$25 to $29.99 • 25%
$30 to $34.99 • 25%
$35 or more • 25%
Yes • 50%
No • 50%
Strong Buy • 25%
Buy • 25%
Hold • 25%
Sell • 25%
Stock price increases by more than 10% • 25%
Stock price increases by 0-10% • 25%
Stock price decreases by 0-10% • 25%
Stock price decreases by more than 10% • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease • 25%
No significant change • 25%
Increases by >10% • 25%
Increases by 0-10% • 25%
Decreases by 0-10% • 25%
Decreases by >10% • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%